Segesterone acetate/ethinylestradiol
Combination hormonal birth control / From Wikipedia, the free encyclopedia
Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin and ethinylestradiol, an estrogen.[1][2][3] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[1][4]
Combination of | |
---|---|
Segesterone acetate | Progestogen |
Ethinylestradiol | Estrogen |
Clinical data | |
Trade names | Annovera |
Other names | EE/SGA; EE/SA |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a604032 |
License data | |
Routes of administration | Intravaginal |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use.[5] Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed and can be stored at temperatures up to 30 degrees Celsius.[1]
The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018.[4][6]